Recombinant ADAMT S-13 as a new alternative for the patients with congenital thrombocytopenic purpura Case report
Article Sidebar
Main Article Content
Abstract
Congenital thrombocytopenic purpura (cTTP), also known as Upshaw–Schulman syndrome is a rare disease, caused by ADAMTS13 deficiency. This condition may result in various complications, including haemolytic anaemia, renal dysfunction or thrombotic events. To this very day, the most common treatment of this condition is transfusion of fresh frozen plasma.
Recently, recombinant ADAMTS13 (rADAMTS13) has been introduced, representing a revolutionary advancement in the treatment of cTTP, and giving patients new, more comfortable alternative.
We present here a case report of a patient with congenital thrombocytopenic purpura, who after 30 years of being treated with FFP transfusions and developing complications from both the disease and its treatment, was successfully transitioned to rADAMTS13 therapy.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Du P, Cristarella T, Goyer C et al. A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Medited Thrombotic Thrombocytopenic Purpura. J Blood Med. 2024; 14: 363-86. https://doi.org/10.2147/JBM.S464365.
3. Sukumar S, Lämmle B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med. 2021; 10(3): 536. https://doi.org/10.3390/jcm10030536.
4. Von Krogh AS, Waage A, Quist-Paulsen P. Congenital thrombotic thrombocytopenic purpura. Tidsskr Nor Legeforen. 2016; 136: 1452-7. https://doi.org/10.4045/tidsskr.15.1272.
5. Plaimauer B, Kremer Hovinga JA, Juno C et al. Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost. 2011; 9: 936-44. https://doi.org/10.1111/j.1538-7836.2011.04224.x.
6. Matsumoto M, Miyakawa Y, Kokame K et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023. Int J Hematol. 2023; 118: 529-46. https://doi.org/10.1007/s12185-023-03657-0.
7. Nusrat S, Beg K, Khan O et al. Hereditary Thrombotic Thrombocytopenic Purpura. Genes. 2023; 14(10): 8. https://doi.org/10.3390/genes14101956.
8. Asmis LM, Serra A, Krafft A et al. Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2002; 387: 2356-61. https://doi.org/10.1056/NEJMoa2211113.
9. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024; 105: 137. https://doi.org/10.1016/j.kint.2023.10.018.
10. Bendapudi PK, Foy BH, Mueller SB et al. Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2024; 390(18): 1690-8. https://doi.org/10.1056/NEJMoa2402567.
11. Lämmle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost. 2005; 3: 1663-75. https://doi.org/10.1111/j.1538-7836.2005.01425.x .
12. Sharma S, Sharma P, Tyler LN. Transfusion of Blood and Blood Products: Indications and Complications. Am Fam Physician. 2011; 83(6): 719-24.
13. Altobelli C, Anastasio P, Cerrone A et al. Therapeutic Plasmapheresis: A Revision of Literature. Kidney Blood Press Res. 2023; 48(1): 66-78. https://doi.org/10.1159/000528556.
14. Takeda Manufacturing Austria AG. ADZYNMA (recombinant ADAMTS13): prescribing information and patient leaflet. 2023.
15. Cresente M, Thomas GM, Demers M et al. ADAMTS13 exerts a thrombolytic effect in microcirculation. Thromb Haemost. 2012; 108(3): 527-32. https://doi.org/10.1160/TH12-01-0046.
16. Plaimauer B, Schiviz A, Kaufmann S et al. Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS‐13 activity levels in inhibitortreated rats by the use of defined doses of recombinant ADAMTS‐13. J Thromb Haemost. 2015; 13: 2053-62. https://doi.org/10.1111/jth.13137.
17. Scully M, Antun A, Cataland SR et al. Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2024; 390: 1584-96. https://doi.org/10.1056/NEJMoa2314793.